4//SEC Filing
Rawcliffe Adrian 4
Accession 0001104659-25-015739
CIK 0001621227other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:30 PM ET
Size
8.9 KB
Accession
0001104659-25-015739
Insider Transaction Report
Form 4
Rawcliffe Adrian
DirectorChief Executive Officer
Transactions
- Award
Option to purchase Ordinary Shares
2025-02-20+5,143,248→ 5,143,248 totalExercise: $0.10Exp: 2035-02-20→ Ordinary Shares (5,143,248 underlying) - Award
Option to purchase Ordinary Shares
2025-02-20+3,428,832→ 3,428,832 totalExercise: $0.00→ Ordinary Shares (3,428,832 underlying)
Footnotes (5)
- [F1]The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
- [F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001555851
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 5:30 PM ET
- Size
- 8.9 KB